# Clinical trial results:
# A randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathy

## Summary

| | |
|---|---|
| EudraCT number | 2012-004179-38 |
| Trial protocol | AT SE FI NL DE NO HU PT DK BG IT ES PL CZ |
| Global end of trial date | 07 August 2014 |

**Results information**

| | |
|---|---|
| Result version number | v3 (current) |
| This version publication date | 16 July 2021 |
| First version publication date | 08 August 2015 |
| Version creation reason | • Correction of full data set<br>minor update |

## Trial information

**Trial identification**

| | |
|---|---|
| Sponsor protocol code | BAY94-8862/16243 |

**Additional study identifiers**

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01874431 |
| WHO universal trial number (UTN) | - |

Notes:

**Sponsors**

| | |
|---|---|
| Sponsor organisation name | Bayer AG |
| Sponsor organisation address | Kaiser-Wilhelm-Allee, Leverkusen, Germany, D-51368 |
| Public contact | Therapeutic Area Head, Bayer AG, clinical-trials-contact@bayer.com |
| Scientific contact | Therapeutic Area Head, Bayer AG, clinical-trials-contact@bayer.com |

Notes:

**Paediatric regulatory details**

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 07 August 2014 |
| Is this the analysis of the primary completion data? | No |

| | |
|---|---|
| Global end of trial reached? | Yes |
| Global end of trial date | 07 August 2014 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

Primary objective of the study was to investigate the change of urinary albumin-to-creatinine ratio (UACR) after treatment with different oral doses of BAY94-8862 given once daily over 90 days.

Protection of trial subjects:

The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the International Conference on Harmonization guideline E6: Good Clinical Practice. Before entering the study, the informed consent form was read by and explained to all subjects. Participating subjects signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.

Background therapy:

Standard of care for renal and cardiovascular disease (CVD) protection (i.e. according to local guidelines: angiotensin-converting enzyme inhibitor [ACEI] or angiotensin receptor blocker [ARB] and optimal antihypertensive therapy; statins, anti-platelets, and beta-blockers; and glycemic control).

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 12 June 2013 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Australia: 17 |
| Country: Number of subjects enrolled | Austria: 27 |
| Country: Number of subjects enrolled | Bulgaria: 84 |
| Country: Number of subjects enrolled | Canada: 38 |
| Country: Number of subjects enrolled | Czech Republic: 27 |
| Country: Number of subjects enrolled | Denmark: 71 |
| Country: Number of subjects enrolled | Finland: 52 |
| Country: Number of subjects enrolled | France: 14 |
| Country: Number of subjects enrolled | Germany: 14 |
| Country: Number of subjects enrolled | Hong Kong: 7 |
| Country: Number of subjects enrolled | Hungary: 25 |
| Country: Number of subjects enrolled | Israel: 64 |
| Country: Number of subjects enrolled | Italy: 82 |
| Country: Number of subjects enrolled | Netherlands: 22 |
| Country: Number of subjects enrolled | Norway: 7 |

| | |
|---|---|
| Country: Number of subjects enrolled | Poland: 23 |
| Country: Number of subjects enrolled | Portugal: 9 |
| Country: Number of subjects enrolled | South Africa: 51 |
| Country: Number of subjects enrolled | Korea, Republic of: 12 |
| Country: Number of subjects enrolled | Spain: 67 |
| Country: Number of subjects enrolled | Sweden: 45 |
| Country: Number of subjects enrolled | Taiwan: 22 |
| Country: Number of subjects enrolled | United States: 43 |
| Worldwide total number of subjects | 823 |
| EEA total number of subjects | 569 |

Notes:

**Subjects enrolled per age group**

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 388 |
| From 65 to 84 years | 431 |
| 85 years and over | 4 |

## Subject disposition

### Recruitment

Recruitment details:

The study was conducted at 148 study centers in 23 countries, from 12 June 2013 (first subject, first visit) to 07 August 2014 (last subject, last visit). The randomization was stratified by region (Europe, North America, Asia, others [Australia, Israel, and South Africa]), and type of albuminuria at screening (very high or high albuminuria).

### Pre-assignment

Screening details:

Of 1501 subjects screened, 823 were randomized and 821 were treated at 128 study centers.

### Period 1

| | |
|---|---|
| Period 1 title | Treatment Period (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Carer, Assessor |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Finerenone (BAY94-8862) (1.25 mg) |

Arm description:

1.25 milligram (mg) BAY94-8862 tablet once daily in the morning for 90 days.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Finerenone |
| Investigational medicinal product code | BAY94-8862 |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Immediate-release (IR) light orange film-coated tablets, oval (modified oblong), containing 1.25 mg BAY94-8862, were administrated once daily in the morning for 90 days.

| | |
|---|---|
| **Arm title** | Finerenone (BAY94-8862) (2.5 mg) |

Arm description:

2.5 mg  BAY94-8862 tablet once daily in the morning for 90 days.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Finerenone |
| Investigational medicinal product code | BAY94-8862 |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

IR light orange film-coated tablets, oval (modified oblong), containing 2.5 mg BAY94-8862, were administrated once daily in the morning for 90 days.

| | |
|---|---|
| **Arm title** | Finerenone (BAY94-8862) (5 mg) |

Arm description:

5 mg BAY94-8862 tablet once daily in the morning for 90 days.

| | |
|---|---|
| Arm type | Experimental |

| | |
|---|---|
| Investigational medicinal product name | Finerenone |
| Investigational medicinal product code | BAY94-8862 |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

IR light orange film-coated tablets, oval (modified oblong), containing 5 mg BAY94-8862, were administrated once daily in the morning for 90 days.

| **Arm title** | Finerenone (BAY94-8862) (7.5 mg) |
|---|---|

Arm description:

7.5 mg BAY94-8862 tablet once daily in the morning for 90 days.

| Arm type | Experimental |
|---|---|
| Investigational medicinal product name | Finerenone |
| Investigational medicinal product code | BAY 94-8862 |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

IR light orange film-coated tablets, oval (modified oblong), containing 7.5 mg BAY94-8862, were administrated once daily in the morning for 90 days.

| **Arm title** | Finerenone (BAY94-8862) (10 mg) |
|---|---|

Arm description:

10 mg BAY94-8862 tablet once daily in the morning for 90 days.

| Arm type | Experimental |
|---|---|
| Investigational medicinal product name | Finerenone |
| Investigational medicinal product code | BAY94-8862 |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

IR light orange film-coated tablets, oval (modified oblong), containing 10 mg BAY94-8862, were administrated once daily in the morning for 90 days.

| **Arm title** | Finerenone (BAY94-8862) (15 mg) |
|---|---|

Arm description:

15 mg BAY94-8862 tablet once daily in the morning for 90 days.

| Arm type | Experimental |
|---|---|
| Investigational medicinal product name | Finerenone |
| Investigational medicinal product code | BAY94-8862 |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

IR light orange film-coated tablets, oval (modified oblong), containing 15 mg BAY94-8862, were administrated once daily in the morning for 90 days.

| **Arm title** | Finerenone (BAY94-8862) (20 mg) |
|---|---|

Arm description:

20 mg BAY94-8862 tablet once daily in the morning for 90 days

| Arm type | Experimental |
|---|---|

| | |
|---|---|
| Investigational medicinal product name | Finerenone |
| Investigational medicinal product code | BAY94-8862 |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

IR light orange film-coated tablets, oval (modified oblong), containing 20 mg BAY94-8862, were administrated once daily in the morning for 90 days.

| | |
|---|---|
| **Arm title** | Placebo |

Arm description:

Placebo tablet once daily in the morning for 90 days.

| | |
|---|---|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Placebo tablets (matching BAY94-8862 tablets) were administrated once daily in the morning for 90 days.

| **Number of subjects in period 1[1]** | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) |
|---|---|---|---|
| Started | 96 | 92 | 100 |
| Completed | 90 | 87 | 90 |
| Not completed | 6 | 5 | 10 |
| Physician decision | - | - | 1 |
| Consent withdrawn by subject | - | - | 1 |
| Logistical difficulties | - | - | - |
| Protocol violation | 1 | 1 | 1 |
| Adverse event | 5 | 4 | 6 |
| Non-compliance | - | - | - |
| Lost to follow-up | - | - | 1 |
| Sponsor decision | - | - | - |

| **Number of subjects in period 1[1]** | Finerenone (BAY94-8862) (7.5 mg) | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) |
|---|---|---|---|
| Started | 97 | 98 | 125 |
| Completed | 91 | 90 | 114 |
| Not completed | 6 | 8 | 11 |
| Physician decision | - | - | - |
| Consent withdrawn by subject | 1 | 1 | 1 |
| Logistical difficulties | - | - | - |
| Protocol violation | - | 3 | 2 |

| | | | |
|---|---|---|---|
| Adverse event | 5 | 2 | 8 |
| Non-compliance | - | 1 | - |
| Lost to follow-up | - | - | - |
| Sponsor decision | - | 1 | - |

| **Number of subjects in period 1[1]** | Finerenone (BAY94-8862) (20 mg) | Placebo |
|---|---|---|
| Started | 119 | 94 |
| Completed | 112 | 90 |
| Not completed | 7 | 4 |
| Physician decision | - | - |
| Consent withdrawn by subject | 3 | - |
| Logistical difficulties | 1 | - |
| Protocol violation | - | 1 |
| Adverse event | 2 | 3 |
| Non-compliance | 1 | - |
| Lost to follow-up | - | - |
| Sponsor decision | - | - |

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
Justification: Number of subjects received treatment were reported in the baseline period.

## Baseline characteristics

| Reporting groups | |
|---|---|
| Reporting group title | Finerenone (BAY94-8862) (1.25 mg) |
| Reporting group description: | |
| 1.25 milligram (mg) BAY94-8862 tablet once daily in the morning for 90 days. | |
| Reporting group title | Finerenone (BAY94-8862) (2.5 mg) |
| Reporting group description: | |
| 2.5 mg BAY94-8862 tablet once daily in the morning for 90 days. | |
| Reporting group title | Finerenone (BAY94-8862) (5 mg) |
| Reporting group description: | |
| 5 mg BAY94-8862 tablet once daily in the morning for 90 days. | |
| Reporting group title | Finerenone (BAY94-8862) (7.5 mg) |
| Reporting group description: | |
| 7.5 mg BAY94-8862 tablet once daily in the morning for 90 days. | |
| Reporting group title | Finerenone (BAY94-8862) (10 mg) |
| Reporting group description: | |
| 10 mg BAY94-8862 tablet once daily in the morning for 90 days. | |
| Reporting group title | Finerenone (BAY94-8862) (15 mg) |
| Reporting group description: | |
| 15 mg BAY94-8862 tablet once daily in the morning for 90 days. | |
| Reporting group title | Finerenone (BAY94-8862) (20 mg) |
| Reporting group description: | |
| 20 mg BAY94-8862 tablet once daily in the morning for 90 days | |
| Reporting group title | Placebo |
| Reporting group description: | |
| Placebo tablet once daily in the morning for 90 days. | |

| Reporting group values | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) |
|---|---|---|---|
| Number of subjects | 96 | 92 | 100 |
| Age categorical | | | |
| Units: Subjects | | | |
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 64.91 | 64.86 | 63.31 |
| standard deviation | ± 9.57 | ± 9.09 | ± 8.79 |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 18 | 14 | 29 |
| Male | 78 | 78 | 71 |
| Baseline UACR | | | |
| Albumin-to-creatinine ratio (UACR) is defined as gram of albumin per kilogram of creatinine. UACR was determined from 3 first morning void samples taken on 3 consecutive days. | | | |
| Units: G/kg | | | |
| arithmetic mean | 412.02 | 471.01 | 402.04 |
| standard deviation | ± 507.51 | ± 784.84 | ± 535.44 |
| Baseline potassium | | | |
| Units: mmol/L | | | |

| | | | |
|---|---|---|---|
| arithmetic mean | 4.323 | 4.297 | 4.314 |
| standard deviation | ± 0.425 | ± 0.426 | ± 0.325 |
| Baseline eGFR | | | |
| An estimated glomerular filtration rate (eGFR) indicates the renal function. An eGFR was calculated based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. | | | |
| Units: mL/min/1.73m^2 | | | |
| arithmetic mean | 66.113 | 67.425 | 67.080 |
| standard deviation | ± 21.923 | ± 20.164 | ± 22.205 |
| Baseline KDQOL-36 domain score (Effects of Kidney Disease) | | | |
| The Kidney Disease QOL [KDQOL]-36 questionnaire is a specific measure of Health-Related Quality of Life (HRQoL) for chronic kidney disease (CKD) that includes effects and burden of kidney disease as well as physical and mental health scores. Index score ranges from 0 (serve problems in all items) to 100 (no problem in all items). "Effects of Kidney disease" sub-score was analyzed. Data for subjects with valid data for this baseline characteristic were reported. | | | |
| Units: Scores on a scale | | | |
| arithmetic mean | 90.78 | 92.53 | 91.78 |
| standard deviation | ± 10.28 | ± 9.57 | ± 12.55 |
| Baseline EQ-5D scores (EQ5D - Visual Analog Scale) | | | |
| EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L) questionnaires consist of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS was analyzed for this endpoint and it ranges from 0 (worst possible health state) to 100 (best possible health state). Data for subjects with valid data for this baseline characteristic were reported. | | | |
| Units: Score on a scale | | | |
| arithmetic mean | 71.76 | 72.79 | 73.01 |
| standard deviation | ± 16.39 | ± 14.81 | ± 16.21 |

| **Reporting group values** | Finerenone (BAY94-8862) (7.5 mg) | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) |
|---|---|---|---|
| Number of subjects | 97 | 98 | 125 |
| Age categorical | | | |
| Units: Subjects | | | |
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 63.73 | 64.94 | 63.95 |
| standard deviation | ± 10.04 | ± 9.62 | ± 8.34 |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 18 | 21 | 27 |
| Male | 79 | 77 | 98 |
| Baseline UACR | | | |
| Albumin-to-creatinine ratio (UACR) is defined as gram of albumin per kilogram of creatinine. UACR was determined from 3 first morning void samples taken on 3 consecutive days. | | | |
| Units: G/kg | | | |
| arithmetic mean | 405.14 | 441.16 | 450.12 |
| standard deviation | ± 702.63 | ± 571.27 | ± 657.04 |
| Baseline potassium | | | |
| Units: mmol/L | | | |
| arithmetic mean | 4.311 | 4.297 | 4.288 |
| standard deviation | ± 0.435 | ± 0.420 | ± 0.459 |
| Baseline eGFR | | | |
| An estimated glomerular filtration rate (eGFR) indicates the renal function. An eGFR was calculated | | | |

| | | | |
|---|---|---|---|
| based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. | | | |
| Units: mL/min/1.73m^2 | | | |
| arithmetic mean | 67.497 | 67.042 | 67.455 |
| standard deviation | ± 21.917 | ± 20.857 | ± 23.646 |
| Baseline KDQOL-36 domain score (Effects of Kidney Disease) | | | |
| The Kidney Disease QOL [KDQOL]-36 questionnaire is a specific measure of Health-Related Quality of Life (HRQoL) for chronic kidney disease (CKD) that includes effects and burden of kidney disease as well as physical and mental health scores. Index score ranges from 0 (serve problems in all items) to 100 (no problem in all items). "Effects of Kidney disease" sub-score was analyzed. Data for subjects with valid data for this baseline characteristic were reported. | | | |
| Units: Scores on a scale | | | |
| arithmetic mean | 92.99 | 88.71 | 90.45 |
| standard deviation | ± 11.04 | ± 16.50 | ± 14.39 |
| Baseline EQ-5D scores (EQ5D - Visual Analog Scale) | | | |
| EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L) questionnaires consist of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS was analyzed for this endpoint and it ranges from 0 (worst possible health state) to 100 (best possible health state). Data for subjects with valid data for this baseline characteristic were reported. | | | |
| Units: Score on a scale | | | |
| arithmetic mean | 74.49 | 73.89 | 73.19 |
| standard deviation | ± 15.92 | ± 16.47 | ± 16.11 |

| **Reporting group values** | Finerenone (BAY94-8862) (20 mg) | Placebo | Total |
|---|---|---|---|
| Number of subjects | 119 | 94 | 821 |
| Age categorical | | | |
| Units: Subjects | | | |
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 64.7 | 63.26 | |
| standard deviation | ± 9.26 | ± 8.68 | - |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 30 | 25 | 182 |
| Male | 89 | 69 | 639 |
| Baseline UACR | | | |
| Albumin-to-creatinine ratio (UACR) is defined as gram of albumin per kilogram of creatinine. UACR was determined from 3 first morning void samples taken on 3 consecutive days. | | | |
| Units: G/kg | | | |
| arithmetic mean | 379.28 | 377.28 | |
| standard deviation | ± 457.33 | ± 542.27 | - |
| Baseline potassium | | | |
| Units: mmol/L | | | |
| arithmetic mean | 4.294 | 4.254 | |
| standard deviation | ± 0.439 | ± 0.479 | - |
| Baseline eGFR | | | |
| An estimated glomerular filtration rate (eGFR) indicates the renal function. An eGFR was calculated based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. | | | |
| Units: mL/min/1.73m^2 | | | |
| arithmetic mean | 66.039 | 72.213 | |
| standard deviation | ± 22.205 | ± 20.434 | - |

| | | | |
|---|---|---|---|
| Baseline KDQOL-36 domain score (Effects of Kidney Disease) | | | |
| The Kidney Disease QOL [KDQOL]-36 questionnaire is a specific measure of Health-Related Quality of Life (HRQoL) for chronic kidney disease (CKD) that includes effects and burden of kidney disease as well as physical and mental health scores. Index score ranges from 0 (serve problems in all items) to 100 (no problem in all items). "Effects of Kidney disease" sub-score was analyzed. Data for subjects with valid data for this baseline characteristic were reported. | | | |
| Units: Scores on a scale | | | |
| arithmetic mean | 89.10 | 81.45 | |
| standard deviation | ± 17.45 | ± 20.42 | - |
| Baseline EQ-5D scores (EQ5D - Visual Analog Scale) | | | |
| EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L) questionnaires consist of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS was analyzed for this endpoint and it ranges from 0 (worst possible health state) to 100 (best possible health state). Data for subjects with valid data for this baseline characteristic were reported. | | | |
| Units: Score on a scale | | | |
| arithmetic mean | 71.36 | 70.05 | |
| standard deviation | ± 17.49 | ± 17.69 | - |

## End points

### End points reporting groups

| | |
|---|---|
| Reporting group title | Finerenone (BAY94-8862) (1.25 mg) |
| Reporting group description: | |
| 1.25 milligram (mg) BAY94-8862 tablet once daily in the morning for 90 days. | |
| Reporting group title | Finerenone (BAY94-8862) (2.5 mg) |
| Reporting group description: | |
| 2.5 mg BAY94-8862 tablet once daily in the morning for 90 days. | |
| Reporting group title | Finerenone (BAY94-8862) (5 mg) |
| Reporting group description: | |
| 5 mg BAY94-8862 tablet once daily in the morning for 90 days. | |
| Reporting group title | Finerenone (BAY94-8862) (7.5 mg) |
| Reporting group description: | |
| 7.5 mg BAY94-8862 tablet once daily in the morning for 90 days. | |
| Reporting group title | Finerenone (BAY94-8862) (10 mg) |
| Reporting group description: | |
| 10 mg BAY94-8862 tablet once daily in the morning for 90 days. | |
| Reporting group title | Finerenone (BAY94-8862) (15 mg) |
| Reporting group description: | |
| 15 mg BAY94-8862 tablet once daily in the morning for 90 days. | |
| Reporting group title | Finerenone (BAY94-8862) (20 mg) |
| Reporting group description: | |
| 20 mg BAY94-8862 tablet once daily in the morning for 90 days | |
| Reporting group title | Placebo |
| Reporting group description: | |
| Placebo tablet once daily in the morning for 90 days. | |
| Subject analysis set title | Safety Analysis Set (SAF) |
| Subject analysis set type | Safety analysis |
| Subject analysis set description: | |
| SAF (N=821) included all randomized subjects who took at least one dose of study drug and with data after beginning of treatment. | |
| Subject analysis set title | Full Analysis Set (FAS) |
| Subject analysis set type | Full analysis |
| Subject analysis set description: | |
| FAS (N=812) included all subjects of the SAF who had baseline and at least one post-baseline urinary albumin-to-creatinine ratio (UACR) value. | |

### Primary: Ratio of UACR at Day 90 to UACR at Baseline

| | |
|---|---|
| End point title | Ratio of UACR at Day 90 to UACR at Baseline |
| End point description: | |
| Albumin-to-creatinine ratio (UACR) is defined as gram of albumin per kilogram of creatinine. UACR was calculating the average of 3 first morning void samples taken on 3 consecutive days. | |
| End point type | Primary |
| End point timeframe: | |
| Baseline and Day 90±2 | |

| End point values | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) | Finerenone (BAY94-8862) (7.5 mg) |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 96[1] | 92[2] | 98[3] | 96[4] |
| Units: Ratio | | | | |
| least squares mean (confidence interval 90%) | 0.869 (0.772 to 0.979) | 0.89 (0.786 to 1.009) | 0.824 (0.73 to 0.929) | 0.739 (0.653 to 0.835) |

Notes:

[1] - FAS

[2] - FAS

[3] - FAS

[4] - FAS

| End point values | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) | Finerenone (BAY94-8862) (20 mg) | Placebo |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 96[5] | 123[6] | 117[7] | 94[8] |
| Units: Ratio | | | | |
| least squares mean (confidence interval 90%) | 0.708 (0.627 to 0.8) | 0.63 (0.563 to 0.705) | 0.585 (0.523 to 0.654) | 0.938 (0.829 to 1.061) |

Notes:

[5] - FAS

[6] - FAS

[7] - FAS

[8] - FAS

## Statistical analyses

| Statistical analysis title | Statistical analysis 1 |
|---|---|

Statistical analysis description:

To demonstrate a dose-dependent effect of finerenone, an analysis of covariance (ANCOVA) with factors treatment group, type of albuminuria at screening and region, and log-transformed baseline value as covariate nested within type of albuminuria at screening was performed in the FAS using a last-observation carried-forward (LOCF) method for missing observations.

| | |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (1.25 mg) v Placebo |
| Number of subjects included in analysis | 190 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.1973 |
| Method | t-test, 1-sided |
| Parameter estimate | Least square mean ratio |
| Point estimate | 0.926 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.799 |
| upper limit | 1.074 |

| Statistical analysis title | Statistical analysis 2 |
|---|---|

Statistical analysis description:

To demonstrate a dose-dependent effect of finerenone, an ANCOVA with factors treatment group, type of albuminuria at screening and region, and log-transformed baseline value as covariate nested within type of albuminuria at screening was performed in the FAS using a LOCF method for missing observations.

| | |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (2.5 mg) v Placebo |
| Number of subjects included in analysis | 186 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.2808 |
| Method | t-test, 1-sided |
| Parameter estimate | Least square mean ratio |
| Point estimate | 0.949 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.818 |
| upper limit | 1.101 |

| **Statistical analysis title** | Statistical analysis 3 |
|---|---|

Statistical analysis description:

To demonstrate a dose-dependent effect of finerenone, an ANCOVA with factors treatment group, type of albuminuria at screening and region, and log-transformed baseline value as covariate nested within type of albuminuria at screening was performed in the FAS using a LOCF method for missing observations.

| | |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (5 mg) v Placebo |
| Number of subjects included in analysis | 192 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0723 |
| Method | t-test, 1-sided |
| Parameter estimate | Least square mean ratio |
| Point estimate | 0.878 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.758 |
| upper limit | 1.017 |

| **Statistical analysis title** | Statistical analysis 4 |
|---|---|

Statistical analysis description:

To demonstrate a dose-dependent effect of finerenone, an ANCOVA with factors treatment group, type of albuminuria at screening and region, and log-transformed baseline value as covariate nested within type of albuminuria at screening was performed in the FAS using a LOCF method for missing observations.

| | |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (7.5 mg) v Placebo |

| | |
|---|---|
| Number of subjects included in analysis | 190 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0039 |
| Method | t-test, 1-sided |
| Parameter estimate | Least square mean ratio |
| Point estimate | 0.787 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.68 |
| upper limit | 0.912 |

| **Statistical analysis title** | Statistical analysis 5 |
|---|---|

Statistical analysis description:

To demonstrate a dose-dependent effect of finerenone, an ANCOVA with factors treatment group, type of albuminuria at screening and region, and log-transformed baseline value as covariate nested within type of albuminuria at screening was performed in the FAS using a LOCF method for missing observations.

| | |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (10 mg) v Placebo |
| Number of subjects included in analysis | 190 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0009 |
| Method | t-test, 1-sided |
| Parameter estimate | Least square mean ratio |
| Point estimate | 0.755 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.651 |
| upper limit | 0.875 |

| **Statistical analysis title** | Statistical analysis 6 |
|---|---|

Statistical analysis description:

To demonstrate a dose-dependent effect of finerenone, an ANCOVA with factors treatment group, type of albuminuria at screening and region, and log-transformed baseline value as covariate nested within type of albuminuria at screening was performed in the FAS using a LOCF method for missing observations.

| | |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (15 mg) v Placebo |
| Number of subjects included in analysis | 217 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.0001 |
| Method | t-test, 1-sided |
| Parameter estimate | Least square mean ratio |
| Point estimate | 0.671 |

| | |
|---|---|
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.584 |
| upper limit | 0.772 |

| **Statistical analysis title** | Statistical analysis 7 |
|---|---|

Statistical analysis description:

To demonstrate a dose-dependent effect of finerenone, an ANCOVA with factors treatment group, type of albuminuria at screening and region, and log-transformed baseline value as covariate nested within type of albuminuria at screening was performed in the FAS using a LOCF method for missing observations.

| | |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (20 mg) v Placebo |
| Number of subjects included in analysis | 211 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.0001 |
| Method | t-test, 1-sided |
| Parameter estimate | Least square mean ratio |
| Point estimate | 0.624 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.542 |
| upper limit | 0.718 |

## Secondary: Change From Baseline to Day 90 in Serum Potassium

| | |
|---|---|
| End point title | Change From Baseline to Day 90 in Serum Potassium |

End point description:

Data for subjects in the SAF with valid data for this endpoint were reported.

| | |
|---|---|
| End point type | Secondary |

End point timeframe:

Baseline and Day 90±2

| **End point values** | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) | Finerenone (BAY94-8862) (7.5 mg) |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 90 | 87 | 85 | 88 |
| Units: millimole per liter | | | | |
| least squares mean (confidence interval 90%) | 0.109 (0.03 to 0.187) | 0.123 (0.043 to 0.203) | 0.202 (0.122 to 0.282) | 0.127 (0.047 to 0.207) |

| End point values | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) | Finerenone (BAY94-8862) (20 mg) | Placebo |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 87 | 109 | 112 | 90 |
| Units: millimole per liter | | | | |
| least squares mean (confidence interval 90%) | 0.167 (0.087 to 0.248) | 0.238 (0.165 to 0.31) | 0.188 (0.116 to 0.259) | 0.002 (-0.077 to 0.081) |

**Statistical analyses**

| Statistical analysis title | Statistical analysis 1 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (1.25 mg) v Placebo |
| Number of subjects included in analysis | 180 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0428 |
| Method | t-test, 2-sided |
| Parameter estimate | Least squares mean difference |
| Point estimate | 0.107 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.003 |
| upper limit | 0.21 |

| Statistical analysis title | Statistical analysis 2 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (2.5 mg) v Placebo |
| Number of subjects included in analysis | 177 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0223 |
| Method | t-test, 2-sided |
| Parameter estimate | Least squares mean difference |
| Point estimate | 0.121 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.017 |
| upper limit | 0.225 |

| Statistical analysis title | Statistical analysis 3 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (5 mg) v Placebo |

| | |
|---|---|
| Number of subjects included in analysis | 175 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0002 |
| Method | t-test, 2-sided |
| Parameter estimate | Least squares mean difference |
| Point estimate | 0.2 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.096 |
| upper limit | 0.305 |

| **Statistical analysis title** | Statistical analysis 4 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (7.5 mg) v Placebo |
| Number of subjects included in analysis | 178 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0181 |
| Method | t-test, 2-sided |
| Parameter estimate | Least squares mean difference |
| Point estimate | 0.125 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.021 |
| upper limit | 0.229 |

| **Statistical analysis title** | Statistical analysis 5 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (10 mg) v Placebo |
| Number of subjects included in analysis | 177 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0019 |
| Method | t-test, 2-sided |
| Parameter estimate | Least squares mean difference |
| Point estimate | 0.166 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.061 |
| upper limit | 0.27 |

| **Statistical analysis title** | Statistical analysis 6 |
|---|---|

| | |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (15 mg) v Placebo |
| Number of subjects included in analysis | 199 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.0001 |
| Method | t-test, 2-sided |
| Parameter estimate | Least squares mean difference |
| Point estimate | 0.236 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.137 |
| upper limit | 0.334 |

| **Statistical analysis title** | Statistical analysis 7 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (20 mg) v Placebo |
| Number of subjects included in analysis | 202 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0002 |
| Method | t-test, 2-sided |
| Parameter estimate | Least squares mean difference |
| Point estimate | 0.186 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.088 |
| upper limit | 0.284 |

## Secondary: Change From Baseline to Day 90 in eGFR

| | |
|---|---|
| End point title | Change From Baseline to Day 90 in eGFR |

End point description:

An estimated glomerular filtration rate (eGFR) indicates the renal function. An eGFR was calculated based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. Data for subjects in the SAF with valid data for this endpoint were reported.

| | |
|---|---|
| End point type | Secondary |

End point timeframe:

Baseline and Day 90±2

| End point values | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) | Finerenone (BAY94-8862) (7.5 mg) |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 90 | 87 | 85 | 88 |
| Units: mL/min/1.73m^2 | | | | |
| least squares mean (confidence interval 90%) | -2.364 (-4.311 to -0.418) | -3.189 (-5.164 to -1.213) | -2.497 (-4.475 to -0.518) | -3.378 (-5.341 to -1.415) |

| End point values | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) | Finerenone (BAY94-8862) (20 mg) | Placebo |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 87 | 113 | 112 | 90 |
| Units: mL/min/1.73m^2 | | | | |
| least squares mean (confidence interval 90%) | -4.192 (-6.181 to -2.202) | -3.806 (-5.563 to -2.05) | -4.024 (-5.792 to -2.256) | -1.578 (-3.53 to 0.373) |

**Statistical analyses**

| Statistical analysis title | Statistical analysis 1 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (1.25 mg) v Placebo |
| Number of subjects included in analysis | 180 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.5454 |
| Method | t-test, 2-sided |
| Parameter estimate | Least squares mean difference |
| Point estimate | -0.786 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.337 |
| upper limit | 1.765 |

| Statistical analysis title | Statistical analysis 2 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (2.5 mg) v Placebo |
| Number of subjects included in analysis | 177 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.2186 |
| Method | t-test, 2-sided |
| Parameter estimate | Least squares mean difference |
| Point estimate | -1.61 |

| | |
|---|---|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.177 |
| upper limit | 0.957 |

| **Statistical analysis title** | Statistical analysis 3 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (5 mg) v Placebo |
| Number of subjects included in analysis | 175 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.4859 |
| Method | t-test, 2-sided |
| Parameter estimate | Least squares mean difference |
| Point estimate | -0.918 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.503 |
| upper limit | 1.667 |

| **Statistical analysis title** | Statistical analysis 4 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (7.5 mg) v Placebo |
| Number of subjects included in analysis | 178 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.1677 |
| Method | t-test, 2-sided |
| Parameter estimate | Least squares mean difference |
| Point estimate | -1.8 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.358 |
| upper limit | 0.759 |

| **Statistical analysis title** | Statistical analysis 5 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (10 mg) v Placebo |

| | |
|---|---|
| Number of subjects included in analysis | 177 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0462 |
| Method | t-test, 2-sided |
| Parameter estimate | Least squares mean difference |
| Point estimate | -2.613 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -5.183 |
| upper limit | -0.044 |

| **Statistical analysis title** | Statistical analysis 6 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (15 mg) v Placebo |
| Number of subjects included in analysis | 203 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0705 |
| Method | t-test, 2-sided |
| Parameter estimate | Least squares mean difference |
| Point estimate | -2.228 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.643 |
| upper limit | 0.187 |

| **Statistical analysis title** | Statistical analysis 7 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (20 mg) v Placebo |
| Number of subjects included in analysis | 202 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.048 |
| Method | t-test, 2-sided |
| Parameter estimate | Least squares mean difference |
| Point estimate | -2.446 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.869 |
| upper limit | -0.022 |

**Secondary: Change From Baseline to Day 90 in KDQOL-36 Domain Score (Effects of**

| **Kidney Disease)** | |
|---|---|
| End point title | Change From Baseline to Day 90 in KDQOL-36 Domain Score (Effects of Kidney Disease) |

End point description:

The Kidney Disease QOL [KDQOL]-36 questionnaire is a specific measure of Health-Related Quality of Life (HRQoL) for chronic kidney disease (CKD) that includes effects and burden of kidney disease as well as physical and mental health scores. Index score ranges from 0 (severe problems in all items) to 100 (no problem in all items). "Effects of Kidney disease" sub-score was analyzed. Data for subjects in FAS with valid data for this endpoint were reported.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline and Day 90±2

| **End point values** | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) | Finerenone (BAY94-8862) (7.5 mg) |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 89 | 84 | 87 | 89 |
| Units: scores on a scale | | | | |
| least squares mean (confidence interval 95%) | -2.116 (-4.521 to 0.289) | 0.104 (-2.369 to 2.577) | -1.229 (-3.643 to 1.185) | -1.185 (-3.597 to 1.226) |

| **End point values** | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) | Finerenone (BAY94-8862) (20 mg) | Placebo |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 88 | 113 | 109 | 89 |
| Units: scores on a scale | | | | |
| least squares mean (confidence interval 95%) | -2.596 (-5.049 to -0.142) | 0.112 (-2.054 to 2.278) | 0.058 (-2.146 to 2.263) | 0.747 (-1.684 to 3.178) |

## Statistical analyses

| **Statistical analysis title** | Statistical analysis 1 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (1.25 mg) v Placebo |
| Number of subjects included in analysis | 178 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0757 |
| Method | t-test, 2-sided |
| Parameter estimate | Least square mean difference |
| Point estimate | -2.863 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -6.022 |
| upper limit | 0.297 |

| **Statistical analysis title** | Statistical analysis 2 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (2.5 mg) v Placebo |
| Number of subjects included in analysis | 173 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.6941 |
| Method | t-test, 2-sided |
| Parameter estimate | Least square mean difference |
| Point estimate | -0.643 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.851 |
| upper limit | 2.565 |

| **Statistical analysis title** | Statistical analysis 3 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (5 mg) v Placebo |
| Number of subjects included in analysis | 176 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.2228 |
| Method | t-test, 2-sided |
| Parameter estimate | Least square mean difference |
| Point estimate | -1.976 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -5.155 |
| upper limit | 1.203 |

| **Statistical analysis title** | Statistical analysis 4 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (7.5 mg) v Placebo |
| Number of subjects included in analysis | 178 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.2313 |
| Method | t-test, 2-sided |
| Parameter estimate | Least square mean difference |
| Point estimate | -1.932 |

| | |
|---|---|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -5.098 |
| upper limit | 1.234 |

| **Statistical analysis title** | Statistical analysis 5 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (10 mg) v Placebo |
| Number of subjects included in analysis | 177 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0386 |
| Method | t-test, 2-sided |
| Parameter estimate | Least square mean difference |
| Point estimate | -3.342 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -6.509 |
| upper limit | -0.176 |

| **Statistical analysis title** | Statistical analysis 6 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (15 mg) v Placebo |
| Number of subjects included in analysis | 202 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.677 |
| Method | t-test, 2-sided |
| Parameter estimate | Least square mean difference |
| Point estimate | -0.634 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.624 |
| upper limit | 2.355 |

| **Statistical analysis title** | Statistical analysis 7 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (20 mg) v Placebo |

| | |
|---|---|
| Number of subjects included in analysis | 198 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.6536 |
| Method | t-test, 2-sided |
| Parameter estimate | Least square mean difference |
| Point estimate | -0.688 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.699 |
| upper limit | 2.322 |

## Secondary: Change From Baseline to Day 90 in EQ-5D Scores (EQ5D - Visual Analog Scale)

| | |
|---|---|
| End point title | Change From Baseline to Day 90 in EQ-5D Scores (EQ5D - Visual Analog Scale) |

End point description:

EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L) questionnaires consist of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. EQ VAS was analyzed for this endpoint and it ranges from 0 (worst possible health state) to 100 (best possible health state). Data for subjects in FAS with valid data for this endpoint were reported.

| | |
|---|---|
| End point type | Secondary |

End point timeframe:

Baseline and Day 90±2

| End point values | Finerenone (BAY94-8862) (1.25 mg) | Finerenone (BAY94-8862) (2.5 mg) | Finerenone (BAY94-8862) (5 mg) | Finerenone (BAY94-8862) (7.5 mg) |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 89 | 83 | 86 | 89 |
| Units: scores on a scale | | | | |
| least squares mean (confidence interval 95%) | 1.381 (-1.22 to 3.982) | 3.888 (1.208 to 6.568) | 3.124 (0.494 to 5.754) | 2.851 (0.241 to 5.461) |

| End point values | Finerenone (BAY94-8862) (10 mg) | Finerenone (BAY94-8862) (15 mg) | Finerenone (BAY94-8862) (20 mg) | Placebo |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 86 | 112 | 109 | 88 |
| Units: scores on a scale | | | | |
| least squares mean (confidence interval 95%) | 2.698 (0.026 to 5.37) | 2.743 (0.394 to 5.092) | 1.914 (-0.465 to 4.292) | 4.425 (1.794 to 7.057) |

## Statistical analyses

| **Statistical analysis title** | Statistical analysis 1 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (1.25 mg) v Placebo |
| Number of subjects included in analysis | 177 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0816 |
| Method | t-test, 2-sided |
| Parameter estimate | Least square mean difference |
| Point estimate | -3.044 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -6.471 |
| upper limit | 0.383 |

| **Statistical analysis title** | Statistical analysis 2 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (2.5 mg) v Placebo |
| Number of subjects included in analysis | 171 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.7625 |
| Method | t-test, 2-sided |
| Parameter estimate | Least square mean difference |
| Point estimate | -0.537 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.027 |
| upper limit | 2.953 |

| **Statistical analysis title** | Statistical analysis 3 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (5 mg) v Placebo |

| | |
|---|---|
| Number of subjects included in analysis | 174 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.4603 |
| Method | t-test, 2-sided |
| Parameter estimate | Least square mean difference |
| Point estimate | -1.301 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.759 |
| upper limit | 2.157 |

| **Statistical analysis title** | Statistical analysis 4 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (7.5 mg) v Placebo |
| Number of subjects included in analysis | 177 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.3678 |
| Method | t-test, 2-sided |
| Parameter estimate | Least square mean difference |
| Point estimate | -1.574 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -5.004 |
| upper limit | 1.855 |

| **Statistical analysis title** | Statistical analysis 5 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (10 mg) v Placebo |
| Number of subjects included in analysis | 174 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.3279 |
| Method | t-test, 2-sided |
| Parameter estimate | Least square mean difference |
| Point estimate | -1.727 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -5.191 |
| upper limit | 1.736 |

| **Statistical analysis title** | Statistical analysis 6 |
|---|---|

| | |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (15 mg) v Placebo |
| Number of subjects included in analysis | 200 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.3102 |
| Method | t-test, 2-sided |
| Parameter estimate | Least square mean difference |
| Point estimate | -1.682 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.935 |
| upper limit | 1.57 |

| **Statistical analysis title** | Statistical analysis 7 |
|---|---|
| Comparison groups | Finerenone (BAY94-8862) (20 mg) v Placebo |
| Number of subjects included in analysis | 197 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.1317 |
| Method | t-test, 2-sided |
| Parameter estimate | Least square mean difference |
| Point estimate | -2.511 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -5.778 |
| upper limit | 0.755 |

## Adverse events

| Adverse events information | |
|---|---|
| Timeframe for reporting adverse events: Up to approximately 93 days after the start of study drug | |
| Assessment type | Non-systematic |
| **Dictionary used** | |
| Dictionary name | MedDRA |
| Dictionary version | 17.0 |
| **Reporting groups** | |
| Reporting group title | Finerenone (BAY 94-8862) (1.25 mg) |
| Reporting group description: 1.25 milligram (mg) BAY 94-8862 tablet once daily in the morning for 90 days | |
| Reporting group title | Finerenone (BAY 94-8862)(2.5 mg) |
| Reporting group description: 2.5 mg BAY 94-8862 tablet once daily in the morning for 90 days | |
| Reporting group title | Finerenone (BAY 94-8862)(5 mg) |
| Reporting group description: 5 mg BAY 94-8862 tablet once daily in the morning for 90 days | |
| Reporting group title | Finerenone (BAY 94-8862)(7.5 mg) |
| Reporting group description: 7.5 mg BAY 94-8862 tablet once daily in the morning for 90 days | |
| Reporting group title | Finerenone (BAY 94-8862)(10 mg) |
| Reporting group description: 10 mg BAY 94-8862 tablet once daily in the morning for 90 days | |
| Reporting group title | Finerenone (BAY 94-8862)(20 mg) |
| Reporting group description: 20 mg BAY 94-8862 tablet once daily in the morning for 90 days | |
| Reporting group title | Finerenone (BAY 94-8862)(15 mg) |
| Reporting group description: 15 mg BAY 94-8862 tablet once daily in the morning for 90 days | |
| Reporting group title | Placebo |
| Reporting group description: Placebo tablet once daily in the morning for 90 days | |

| Serious adverse events | Finerenone (BAY 94-8862) (1.25 mg) | Finerenone (BAY 94-8862)(2.5 mg) | Finerenone (BAY 94-8862)(5 mg) |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 5 / 96 (5.21%) | 3 / 92 (3.26%) | 7 / 100 (7.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Bladder cancer | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostate cancer | | | |
| subjects affected / exposed | 1 / 96 (1.04%) | 0 / 92 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Hypertensive crisis | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral artery stenosis | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Surgical and medical procedures | | | |
| Coronary artery bypass | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Toe amputation | | | |
| subjects affected / exposed | 1 / 96 (1.04%) | 0 / 92 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Local swelling | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 1 / 92 (1.09%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Investigations | | | |
| Blood potassium increased | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 1 / 92 (1.09%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatic enzymes increased | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 1 / 92 (1.09%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Subdural haemorrhage | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 1 / 100 (1.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Acute myocardial infarction | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac failure | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 1 / 100 (1.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary artery disease | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Cerebrovascular accident | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular disorder | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 1 / 100 (1.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subarachnoid haemorrhage | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 1 / 100 (1.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ischaemic stroke | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders | | | |
| Angle closure glaucoma | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 1 / 100 (1.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholecystitis | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 1 / 100 (1.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Renal impairment | | | |
| subjects affected / exposed | 1 / 96 (1.04%) | 0 / 92 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 1 / 100 (1.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Subcutaneous abscess | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 96 (0.00%) | 0 / 92 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 2 / 96 (2.08%) | 0 / 92 (0.00%) | 1 / 100 (1.00%) |
| occurrences causally related to treatment / all | 2 / 2 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 1 / 96 (1.04%) | 0 / 92 (0.00%) | 0 / 100 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| **Serious adverse events** | Finerenone (BAY 94-8862)(7.5 mg) | Finerenone (BAY 94-8862)(10 mg) | Finerenone (BAY 94-8862)(20 mg) |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 8 / 97 (8.25%) | 2 / 98 (2.04%) | 4 / 119 (3.36%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |

| | | | |
|---|---|---|---|
| Bladder cancer | | | |
| subjects affected / exposed | 0 / 97 (0.00%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostate cancer | | | |
| subjects affected / exposed | 1 / 97 (1.03%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Hypertensive crisis | | | |
| subjects affected / exposed | 0 / 97 (0.00%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral artery stenosis | | | |
| subjects affected / exposed | 0 / 97 (0.00%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Surgical and medical procedures | | | |
| Coronary artery bypass | | | |
| subjects affected / exposed | 1 / 97 (1.03%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Toe amputation | | | |
| subjects affected / exposed | 0 / 97 (0.00%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Local swelling | | | |
| subjects affected / exposed | 0 / 97 (0.00%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 97 (0.00%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Blood potassium increased | | | |
| subjects affected / exposed | 1 / 97 (1.03%) | 0 / 98 (0.00%) | 1 / 119 (0.84%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatic enzymes increased | | | |
| subjects affected / exposed | 0 / 97 (0.00%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Subdural haemorrhage | | | |
| subjects affected / exposed | 0 / 97 (0.00%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Acute myocardial infarction | | | |
| subjects affected / exposed | 0 / 97 (0.00%) | 1 / 98 (1.02%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 97 (0.00%) | 0 / 98 (0.00%) | 1 / 119 (0.84%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac failure | | | |
| subjects affected / exposed | 0 / 97 (0.00%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary artery disease | | | |
| subjects affected / exposed | 1 / 97 (1.03%) | 1 / 98 (1.02%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Nervous system disorders | | | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 1 / 97 (1.03%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular disorder | | | |
| subjects affected / exposed | 0 / 97 (0.00%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subarachnoid haemorrhage | | | |
| subjects affected / exposed | 0 / 97 (0.00%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 1 / 97 (1.03%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ischaemic stroke | | | |
| subjects affected / exposed | 0 / 97 (0.00%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders | | | |
| Angle closure glaucoma | | | |
| subjects affected / exposed | 0 / 97 (0.00%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholecystitis | | | |
| subjects affected / exposed | 0 / 97 (0.00%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Renal impairment | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 97 (0.00%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 0 / 97 (0.00%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Subcutaneous abscess | | | |
| subjects affected / exposed | 1 / 97 (1.03%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |
| subjects affected / exposed | 1 / 97 (1.03%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 97 (0.00%) | 1 / 98 (1.02%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 1 / 97 (1.03%) | 0 / 98 (0.00%) | 2 / 119 (1.68%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 0 / 97 (0.00%) | 0 / 98 (0.00%) | 0 / 119 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| **Serious adverse events** | Finerenone (BAY 94-8862)(15 mg) | Placebo | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 6 / 125 (4.80%) | 3 / 94 (3.19%) | |

| | | | |
|---|---|---|---|
| number of deaths (all causes) | 1 | 1 | |
| number of deaths resulting from adverse events | 0 | 0 | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Bladder cancer | | | |
| subjects affected / exposed | 1 / 125 (0.80%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prostate cancer | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular disorders | | | |
| Hypertensive crisis | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 1 / 94 (1.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral artery stenosis | | | |
| subjects affected / exposed | 1 / 125 (0.80%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Surgical and medical procedures | | | |
| Coronary artery bypass | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Toe amputation | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Local swelling | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 1 / 94 (1.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|---|---|---|
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Investigations | | | |
| Blood potassium increased | | | |
| subjects affected / exposed | 2 / 125 (1.60%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancreatic enzymes increased | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury, poisoning and procedural complications | | | |
| Subdural haemorrhage | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Acute myocardial infarction | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac failure | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery disease | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 1 / 94 (1.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebrovascular disorder | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subarachnoid haemorrhage | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Syncope | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ischaemic stroke | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 1 / 94 (1.06%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Eye disorders | | | |
| Angle closure glaucoma | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Cholecystitis | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|---|---|---|
| Renal and urinary disorders | | | |
| Renal impairment | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Subcutaneous abscess | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urosepsis | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperkalaemia | | | |
| subjects affected / exposed | 2 / 125 (1.60%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 2 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypoglycaemia | | | |
| subjects affected / exposed | 0 / 125 (0.00%) | 0 / 94 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| **Non-serious adverse events** | Finerenone (BAY 94-8862) (1.25 mg) | Finerenone (BAY 94-8862)(2.5 mg) | Finerenone (BAY 94-8862)(5 mg) |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 14 / 96 (14.58%) | 7 / 92 (7.61%) | 13 / 100 (13.00%) |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 6 / 96 (6.25%) | 1 / 92 (1.09%) | 3 / 100 (3.00%) |
| occurrences (all) | 6 | 1 | 3 |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 5 / 96 (5.21%) | 2 / 92 (2.17%) | 4 / 100 (4.00%) |
| occurrences (all) | 5 | 2 | 4 |
| Infections and infestations | | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 7 / 96 (7.29%) | 4 / 92 (4.35%) | 8 / 100 (8.00%) |
| occurrences (all) | 7 | 4 | 8 |

| **Non-serious adverse events** | Finerenone (BAY 94-8862)(7.5 mg) | Finerenone (BAY 94-8862)(10 mg) | Finerenone (BAY 94-8862)(20 mg) |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 11 / 97 (11.34%) | 10 / 98 (10.20%) | 12 / 119 (10.08%) |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 1 / 97 (1.03%) | 3 / 98 (3.06%) | 1 / 119 (0.84%) |
| occurrences (all) | 1 | 3 | 1 |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 2 / 97 (2.06%) | 2 / 98 (2.04%) | 5 / 119 (4.20%) |
| occurrences (all) | 2 | 2 | 5 |
| Infections and infestations | | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 9 / 97 (9.28%) | 5 / 98 (5.10%) | 8 / 119 (6.72%) |
| occurrences (all) | 9 | 5 | 9 |

| **Non-serious adverse events** | Finerenone (BAY 94-8862)(15 mg) | Placebo | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 11 / 125 (8.80%) | 8 / 94 (8.51%) | |
| Nervous system disorders | | | |
| Dizziness | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed<br>occurrences (all) | 5 / 125 (4.00%)<br>5 | 2 / 94 (2.13%)<br>2 | |
| Gastrointestinal disorders<br>Diarrhoea<br>subjects affected / exposed<br>occurrences (all) | <br><br>3 / 125 (2.40%)<br>4 | <br><br>2 / 94 (2.13%)<br>2 | |
| Infections and infestations<br>Nasopharyngitis<br>subjects affected / exposed<br>occurrences (all) | <br><br>4 / 125 (3.20%)<br>4 | <br><br>5 / 94 (5.32%)<br>6 | |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 04 December 2013 | Amendment 1 was implemented globally. In this amendment changes to ensure consistency within the document and the central and local laboratory as well as clarifications of the study procedure have been implemented. |

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

### Online references

http://www.ncbi.nlm.nih.gov/pubmed/26325557

http://www.ncbi.nlm.nih.gov/pubmed/31583611

http://www.ncbi.nlm.nih.gov/pubmed/33107592